Neutralizing antibodies: Mechanism of neutralization and protective activity against HIV-1

Immunologic Research

Volumn 25, Issue 3, 2002, Pages 193-200

  Xiao, Yi ^a   Dong, Xiaonan ^a   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

HIV 1; Neutralization; Neutralizing antibody; Prevention; Vaccine

Indexed keywords

EPITOPE; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIGENICITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MACACA; MICE; MICE, SCID; NEUTRALIZATION TESTS;

EID: 0036235557     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:25:3:193     Document Type: Review

References (48)

1. HIV vaccines: Prospects and challenges
2. Immunological and virological analyses of persons infected by human-immunodeficiency-virus type-1 while participating in trials of recombinant gp120 subunit vaccines
3. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
4. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
5. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
6. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
7. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
8. Cross-clade neutralization of primary isolates of human immunodeficiency virus 1 by human monoclonal antibodies and tetrameric CD4-IgG
9. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
10. Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus
11. The great escape - AIDS viruses and immune control
12. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
13. A vaccine for HIV type 1: The antibody perspective
14. Cross-clade neutralization of primary isolates of human immunodeficiency virus 1 by human monoclonal antibodies and tetrameric CD4-IgG
15. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries
16. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
17. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro
18. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
19. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1
20. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5
21. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions
22. HIV type 1 coreceptors, neutralization serotypes, and vaccine development
23. Capture of an early fusion-active conformation of HIV-1 gp41
24. Blocking HIV entry
25. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements
26. HIV neutralizing IgA in exposed seronegative subjects recognise an epitope within the gp41 coiled-coil pocket
27. Why do we not have an HIV vaccine and how can we make one?
28. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization
29. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex
30. Immunogenic and antigenic dominance of a non-neutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: Its deletion leads to a strong neutralizing response
31. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
32. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma
33. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
34. Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia
35. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera
36. Virological and immunological characterization of long-term survivors of human-immunodeficiency-virus type-1 infection
37. Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection
38. Glimmerings of hope from the bottom of the well
39. Immune correlates of protection from HIV and AIDS - More answers but yet more questions
40. Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?
41. Viral persistence in vivo through selection of neutralizing antibody-escape variants
42. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope
43. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection
44. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
45. Back to primary school
46. Epitope-vaccine: A new strategy against HIV-1
47. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1
48. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody